137 related articles for article (PubMed ID: 32552139)
21. The dilemma of renin-angiotensin system inhibitors in coronavirus disease 2019 (COVID-19): insights into lung fluid handling and gas exchange in heart failure patients.
Guazzi M; Moroni A
Eur J Heart Fail; 2020 Jun; 22(6):926-928. PubMed ID: 32438449
[No Abstract] [Full Text] [Related]
22. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.
Conversano A; Melillo F; Napolano A; Fominskiy E; Spessot M; Ciceri F; Agricola E
Hypertension; 2020 Aug; 76(2):e10-e12. PubMed ID: 32383626
[No Abstract] [Full Text] [Related]
23. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
[TBL] [Abstract][Full Text] [Related]
24. Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic.
Vázquez-Cornejo E
Bol Med Hosp Infant Mex; 2020; 77(5):274-281. PubMed ID: 33064690
[TBL] [Abstract][Full Text] [Related]
25. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.
Vaduganathan M; Vardeny O; Michel T; McMurray JJV; Pfeffer MA; Solomon SD
N Engl J Med; 2020 Apr; 382(17):1653-1659. PubMed ID: 32227760
[No Abstract] [Full Text] [Related]
26. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19.
Kreutz R; Algharably EAE; Azizi M; Dobrowolski P; Guzik T; Januszewicz A; Persu A; Prejbisz A; Riemer TG; Wang JG; Burnier M
Cardiovasc Res; 2020 Aug; 116(10):1688-1699. PubMed ID: 32293003
[TBL] [Abstract][Full Text] [Related]
27. Anticoagulation in COVID-19: DDI Perspective.
Khiali S; Entezari-Maleki T
Clin Appl Thromb Hemost; 2020; 26():1076029620959457. PubMed ID: 32936672
[No Abstract] [Full Text] [Related]
28. COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient.
Beerkens F; John M; Puliafito B; Corbett V; Edwards C; Tremblay D
Am J Hematol; 2020 Jul; 95(7):E154-E156. PubMed ID: 32243621
[No Abstract] [Full Text] [Related]
29. COVID-19: ACE2centric Infective Disease?
Verdecchia P; Cavallini C; Spanevello A; Angeli F
Hypertension; 2020 Aug; 76(2):294-299. PubMed ID: 32476472
[TBL] [Abstract][Full Text] [Related]
30. Angiotensin receptor blockers and COVID-19.
Saavedra JM
Pharmacol Res; 2020 Jun; 156():104832. PubMed ID: 32304747
[TBL] [Abstract][Full Text] [Related]
31. Controversy regarding ACE inhibitors / ARBs in COVID-19.
Soria Arcos F; Romero Puche A; Vicente Vera T
Rev Esp Cardiol (Engl Ed); 2020 Jun; 73(6):516. PubMed ID: 32371022
[No Abstract] [Full Text] [Related]
32. EMA advice on renin-angiotensin system medicines during covid-19 pandemic.
Drug Ther Bull; 2020 Jun; 58(6):85. PubMed ID: 32295811
[TBL] [Abstract][Full Text] [Related]
33. COVID-19 and the cardiovascular system.
Zheng YY; Ma YT; Zhang JY; Xie X
Nat Rev Cardiol; 2020 May; 17(5):259-260. PubMed ID: 32139904
[TBL] [Abstract][Full Text] [Related]
34. Sildenafil for Pulmonary Arterial Hypertension.
Bhogal S; Khraisha O; Al Madani M; Treece J; Baumrucker SJ; Paul TK
Am J Ther; 2019; 26(4):e520-e526. PubMed ID: 30946047
[TBL] [Abstract][Full Text] [Related]
35. Impact of antihypertensive agents on clinical course and in-hospital mortality: analysis of 169 hypertensive patients hospitalized for COVID-19.
Kocayigit I; Kocayigit H; Yaylaci S; Can Y; Erdem AF; Karabay O
Rev Assoc Med Bras (1992); 2020; 66Suppl 2(Suppl 2):71-76. PubMed ID: 32965360
[TBL] [Abstract][Full Text] [Related]
36. Do ACE inhibitors and angiotensin receptor antagonists increase the risk of severe COVID-19?
Aamodt AH; Bjørk MH; Tronvik EA; Buanes EA; Stovner LJ; Atar D
Tidsskr Nor Laegeforen; 2020 Jun; 140(9):. PubMed ID: 32549022
[No Abstract] [Full Text] [Related]
37. Saudi Epilepsy Society consensus on epilepsy management during the COVID-19 Pandemic.
Alotaibi F; Althani Z; Aljaafari D; Tayeb HO; Baarmah D; Aljalal N; Muthaffar O; Alqulaiti K; Alhameed M; Ali B; Qureshi S; Albaradie R
Neurosciences (Riyadh); 2020 Jul; 25(3):222-225. PubMed ID: 32683406
[No Abstract] [Full Text] [Related]
38. Opioid Use Disorder Treatment and Potential Interactions With Novel COVID-19 Medications: A Clinical Perspective.
Mansuri Z; Shah B; Trivedi C; Beg U; Patel H; Jolly T
Prim Care Companion CNS Disord; 2020 Jul; 22(4):. PubMed ID: 32628368
[No Abstract] [Full Text] [Related]
39. Efficacy of Sildenafil in Patients with Severe COVID-19 and Pulmonary Arterial Hypertension.
Oliynyk OV; Rorat M; Strepetova OV; Dubrov SO; Guryanov VG; Oliynyk YV; Kulivets OS; Ślifirczyk A; Barg W
Viruses; 2023 May; 15(5):. PubMed ID: 37243243
[TBL] [Abstract][Full Text] [Related]
40. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis.
Pirola CJ; Sookoian S
J Infect; 2020 Aug; 81(2):276-281. PubMed ID: 32474043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
